In targeted therapy, studies on KRAS G12C-mutated colorectal cancer have demonstrated significant efficacy of Sotorasib (AMG 510) as a monotherapy, while combining it with anti-EGFR agents like Panitumumab is being explored to address resistance and improve outcomes [445–447]. This evidence concerns the gene KRAS and colorectal cancer.